Quarterly ResultAug 10, 2026, 09:10 AM
NeOnc Technologies Q2 Net Loss $14.2M; NEO100 Phase 2a Results Aug 12
AI Summary
NeOnc Technologies Holdings, Inc. reported a net loss of $14.2 million, or $(0.58) per diluted share, for Q2 2026, compared to $5.7 million in Q2 2025, primarily due to increased R&D investment. The company announced the completion of topline analysis for its Phase 2a NEO100 study, with results to be presented on August 12, 2026. NeOnc also secured UAE IND approvals for both NEO100 and NEO212, expanded its Board with Nasim Shomali, and maintained access to capital resources including a $10.0 million line of credit.
Key Highlights
- Net loss was $14.2 million, or $(0.58) per diluted share, compared to $5.7 million in Q2 2025.
- Research and development expenses increased to $2.6 million from $0.7 million in Q2 2025.
- General and administrative expenses decreased to $0.9 million from $1.0 million in Q2 2025.
- Cash and cash equivalents were approximately $2.0 million as of June 30, 2026.
- Company has an undrawn $10.0 million line of credit with HCWG.
- Approximately $44.5 million remained available under the Mast Hill equity purchase facility.
- Topline results from Phase 2a NEO100 study will be presented on August 12, 2026.
- Received UAE IND approvals for both NEO100 and NEO212 in June.
Price Impact
More from NTHI